Waldencast plc (WALD) Fair Value & Analysis
Consumer Defensive · US · Market cap $200M
Fair value as of: Jun 25, 2026
Analysis
Waldencast plc (WALD) currently trades at $1.53, while our model-based Fair Value estimate is $2.62 — implying the stock looks roughly 71.2% undervalued today. We read business quality at 88/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Waldencast plc operates in the beauty and wellness industry in the United States, Canada, Europe, the Middle East, India, Australia, and New Zealand. The company operates through two segments, Obagi Medical and Milk Makeup. It offers skin care products to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and protect and enhance skin tone and texture; cosmetics; and other beauty products. In addition, the company provides foundation, concealer, primer, blush, setting spray, and bronzer categories, as well as sells liner, eyeshadow, and lip color products. It serves distributors, retailers, physicians, and directly to consumers through its e-commerce platforms, and third-party logistics and delivery providers. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Waldencast plc (WALD) undervalued?
What is the fair value of WALD?
What is the quality score of WALD?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.